Does the media prefer ZBIO or MYGN?

In the previous week, Myriad Genetics had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Myriad Genetics and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.80 beat Myriad Genetics' score of -0.39 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral

Is MYGN or INVA more profitable?

Innoviva has a net margin of 119.89% compared to Myriad Genetics' net margin of -13.96%. Innoviva's return on equity of 33.33% beat Myriad Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -13.96% -16.09% -8.10% Innoviva 119.89% 33.33% 22.67%

Does the media refer more to MYGN or INVA?

In the previous week, Myriad Genetics had 5 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for Myriad Genetics and 10 mentions for Innoviva. Innoviva's average media sentiment score of 1.00 beat Myriad Genetics' score of -0.39 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is MYGN or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -13.96%. MannKind's return on equity of -11.21% beat Myriad Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -13.96% -16.09% -8.10% MannKind -6.63% -11.21% -3.92%

Does the media refer more to MYGN or MNKD?

In the previous week, Myriad Genetics had 2 more articles in the media than MannKind. MarketBeat recorded 15 mentions for Myriad Genetics and 13 mentions for MannKind. MannKind's average media sentiment score of 0.93 beat Myriad Genetics' score of -0.39 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral MannKind 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NVAX or MYGN?

Novavax has higher revenue and earnings than Myriad Genetics. Novavax is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.08 $440.30M -$0.58 N/A Myriad Genetics $824.50M 0.35 -$365.90M -$1.19 N/A

Is NVAX or MYGN more profitable?

Myriad Genetics has a net margin of -13.96% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Myriad Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Myriad Genetics -13.96% -16.09% -8.10%

Does the media prefer NVAX or MYGN?

In the previous week, Myriad Genetics had 7 more articles in the media than Novavax. MarketBeat recorded 15 mentions for Myriad Genetics and 8 mentions for Novavax. Novavax's average media sentiment score of -0.01 beat Myriad Genetics' score of -0.39 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral

Does the media refer more to MYGN or LXRX?

In the previous week, Myriad Genetics had 11 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 15 mentions for Myriad Genetics and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.51 beat Myriad Genetics' score of -0.39 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Myriad Genetics (MYGN) Competitors

$3.02 +0.16 (+5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$3.09 +0.07 (+2.28%)

As of 07:55 PM Eastern

Compare

MYGN vs. ZBIO, INVA, MNKD, NVAX, and LXRX

Should you buy Myriad Genetics stock or one of its competitors? MarketBeat compares Myriad Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Myriad Genetics include Zenas BioPharma (ZBIO), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

99.0% of Myriad Genetics shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Zenas BioPharma has a beta of -1.03, suggesting that its stock price is 203% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 42.26%. Myriad Genetics has a consensus price target of $5.38, suggesting a potential upside of 77.98%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Myriad Genetics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	196.52	-$377.74M	-$8.47	N/A
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A

In the previous week, Myriad Genetics had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Myriad Genetics and 4 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.80 beat Myriad Genetics' score of -0.39 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral

Summary

Myriad Genetics beats Zenas BioPharma on 9 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Innoviva?

Myriad Genetics (NASDAQ:MYGN) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

In the previous week, Myriad Genetics had 5 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for Myriad Genetics and 10 mentions for Innoviva. Innoviva's average media sentiment score of 1.00 beat Myriad Genetics' score of -0.39 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics presently has a consensus target price of $5.38, indicating a potential upside of 77.98%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 74.29%. Given Myriad Genetics' higher probable upside, equities research analysts plainly believe Myriad Genetics is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has a net margin of 119.89% compared to Myriad Genetics' net margin of -13.96%. Innoviva's return on equity of 33.33% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Innoviva	119.89%	33.33%	22.67%

Myriad Genetics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innoviva has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A
Innoviva	$411.33M	3.73	$271.17M	$6.01	3.46

Summary

Innoviva beats Myriad Genetics on 11 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to MannKind?

Myriad Genetics (NASDAQ:MYGN) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

MannKind has lower revenue, but higher earnings than Myriad Genetics. MannKind is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A
MannKind	$348.97M	3.36	$5.86M	-$0.07	N/A

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Myriad Genetics currently has a consensus price target of $5.38, indicating a potential upside of 77.98%. MannKind has a consensus price target of $9.34, indicating a potential upside of 145.89%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Myriad Genetics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, MannKind has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Myriad Genetics had 2 more articles in the media than MannKind. MarketBeat recorded 15 mentions for Myriad Genetics and 13 mentions for MannKind. MannKind's average media sentiment score of 0.93 beat Myriad Genetics' score of -0.39 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral
MannKind	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has a net margin of -6.63% compared to Myriad Genetics' net margin of -13.96%. MannKind's return on equity of -11.21% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
MannKind	-6.63%	-11.21%	-3.92%

Summary

MannKind beats Myriad Genetics on 11 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Novavax?

Novavax (NASDAQ:NVAX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Novavax has higher revenue and earnings than Myriad Genetics. Novavax is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.08	$440.30M	-$0.58	N/A
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A

53.0% of Novavax shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novavax currently has a consensus target price of $13.00, suggesting a potential upside of 75.44%. Myriad Genetics has a consensus target price of $5.38, suggesting a potential upside of 77.98%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Myriad Genetics had 7 more articles in the media than Novavax. MarketBeat recorded 15 mentions for Myriad Genetics and 8 mentions for Novavax. Novavax's average media sentiment score of -0.01 beat Myriad Genetics' score of -0.39 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral

Myriad Genetics has a net margin of -13.96% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Novavax has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

Summary

Novavax beats Myriad Genetics on 11 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Myriad Genetics (NASDAQ:MYGN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Myriad Genetics presently has a consensus price target of $5.38, suggesting a potential upside of 77.98%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 95.28%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Myriad Genetics had 11 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 15 mentions for Myriad Genetics and 4 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.51 beat Myriad Genetics' score of -0.39 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Myriad Genetics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Myriad Genetics has a net margin of -13.96% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Myriad Genetics' return on equity of -16.09% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.35	-$365.90M	-$1.19	N/A
Lexicon Pharmaceuticals	$49.80M	20.78	-$50.34M	-$0.07	N/A

Summary

Lexicon Pharmaceuticals beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$270.12M	$3.51B	$6.81B	$12.68B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	N/A	7.32	281.02	25.13
Price / Sales	0.35	1,280.67	590.80	93.66
Price / Cash	0.76	44.80	28.64	34.82
Price / Book	0.76	16.89	11.02	6.21
Net Income	-$365.90M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-44.59%	-0.63%	0.56%	0.89%
1 Month Performance	-49.58%	-7.41%	-4.14%	-3.60%
1 Year Performance	-22.76%	49.17%	63.23%	20.46%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	3.2211 of 5 stars	$3.02 +5.6%	$5.38 +78.0%	-26.9%	$270.12M	$824.50M	N/A	2,700	Earnings Report Analyst Forecast Gap Up High Trading Volume
ZBIO Zenas BioPharma	3.4778 of 5 stars	$32.82 +8.0%	$44.29 +34.9%	+104.0%	$1.92B	$10M	N/A	N/A	Gap Up
INVA Innoviva	3.0995 of 5 stars	$21.30 -0.7%	$36.20 +70.0%	+12.6%	$1.58B	$420.69M	3.54	100	News Coverage Positive News Upcoming Earnings Analyst Downgrade
MNKD MannKind	3.2082 of 5 stars	$3.95 -4.4%	$8.97 +127.1%	+4.3%	$1.28B	$348.97M	N/A	400	Upcoming Earnings
NVAX Novavax	2.0403 of 5 stars	$7.49 +0.4%	$13.00 +73.6%	+11.6%	$1.23B	$1.12B	N/A	1,990	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. ZBIO, INVA, MNKD, NVAX, and LXRX

How does Myriad Genetics compare to Zenas BioPharma?

Summary

How does Myriad Genetics compare to Innoviva?

Summary

How does Myriad Genetics compare to MannKind?

Summary

How does Myriad Genetics compare to Novavax?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. ZBIO, INVA, MNKD, NVAX, and LXRX

How does Myriad Genetics compare to Zenas BioPharma?

Do institutionals and insiders hold more shares of ZBIO or MYGN?

Is ZBIO or MYGN more profitable?

Which has more volatility and risk, ZBIO or MYGN?

Do analysts recommend ZBIO or MYGN?

Which has preferable valuation & earnings, ZBIO or MYGN?

Does the media prefer ZBIO or MYGN?

Summary

How does Myriad Genetics compare to Innoviva?

Does the media refer more to MYGN or INVA?

Do analysts recommend MYGN or INVA?

Is MYGN or INVA more profitable?

Which has more risk & volatility, MYGN or INVA?

Do institutionals & insiders have more ownership in MYGN or INVA?

Which has higher valuation & earnings, MYGN or INVA?

Summary

How does Myriad Genetics compare to MannKind?

Which has preferable earnings and valuation, MYGN or MNKD?

Do insiders & institutionals have more ownership in MYGN or MNKD?

Do analysts recommend MYGN or MNKD?

Which has more risk and volatility, MYGN or MNKD?

Does the media refer more to MYGN or MNKD?

Is MYGN or MNKD more profitable?

Summary

How does Myriad Genetics compare to Novavax?

Which has better earnings and valuation, NVAX or MYGN?

Do institutionals and insiders have more ownership in NVAX or MYGN?

Do analysts rate NVAX or MYGN?

Does the media prefer NVAX or MYGN?

Is NVAX or MYGN more profitable?

Which has more volatility & risk, NVAX or MYGN?

Summary

How does Myriad Genetics compare to Lexicon Pharmaceuticals?

Do analysts rate MYGN or LXRX?

Does the media refer more to MYGN or LXRX?

Do institutionals & insiders hold more shares of MYGN or LXRX?

Which has more risk and volatility, MYGN or LXRX?

Is MYGN or LXRX more profitable?

Which has stronger earnings & valuation, MYGN or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools